- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00422630
The Metabolic Effects of Different Weight Loss Diets
Dietary Interventions for Insulin Resistance and the Metabolic Syndrome
Study Overview
Status
Intervention / Treatment
Detailed Description
BACKGROUND:
Several dietary approaches, including the Dietary Approaches to Stop Hypertension study diet (the DASH diet) and the low glycemic index diet (low GI diet), may be helpful for overweight individuals who have the metabolic syndrome. The DASH diet is rich in fruits, vegetables, whole grains, and low-fat dairy products. It also contains moderate amounts of nuts, beans, fish, and poultry. Consumption of red meat, sweets, and sugary beverages is limited. As a result, the DASH diet contains more potassium, magnesium, calcium, and fiber and less total fat, saturated fat, cholesterol, simple sugars, and sodium than the average American diet. The DASH diet has been shown to lower blood pressure and LDL cholesterol ("bad" cholesterol). It has also been shown to be an effective diet for weight loss. It may also reduce inflammation and insulin resistance, two important features of the metabolic syndrome.
Low GI diets are typically lower in carbohydrate content and higher in protein content than the average American diet. Many popular diet books promote the use of low glycemic index diets. In this study, the low GI diet will contain plenty of fruits and vegetables and moderate amounts of nuts, beans, lean meats, fish, and reduced-fat dairy products. Refined grains, potatoes, and sweets will be avoided. The low GI diet can help improve levels of blood sugar and insulin in the blood after meals. It may also help control hunger after meals. Some researchers believe it may promote more weight loss than other diets, especially in people with the metabolic syndrome. The low GI diet may also reduce cholesterol and triglyceride levels.
Although both the DASH diet and the low GI diet appear to have beneficial effects, it is not clear whether one diet is better than the other for people with the metabolic syndrome. It is also not clear whether these diets would be better for weight loss than a reduced-calorie average American diet. This weight loss study has been designed to test the metabolic effects of the DASH diet and the low GI diet, as compared to the average American diet.
STUDY OVERVIEW:
Up to 18 research volunteers will be studied at Rockefeller University Hospital during a multi-phase study of almost 15 weeks duration. This study includes a 2-week run-in period at home, a 19-day inpatient period during which weight will be kept stable, an 8-week outpatient weight loss period, and a 2-week inpatient period of weight stability at a lower body weight. All food will be provided for about 13 weeks (during the inpatient periods and the 8-week outpatient weight loss period). Volunteers will first undergo testing (described below) at baseline, on an average American diet. They will then be randomized to one of three diets (the DASH diet, the low GI diet, or the average American diet). Weight will initially be kept stable for two weeks on the study diet. At the end of the first inpatient period, volunteers will undergo repeat testing to assess the metabolic effects of the diets, in the absence of weight loss. Volunteers will then be discharged to home for 8 weeks, during which they will receive a 50% reduced-calorie study diet. Volunteers will return to Rockefeller University Hospital twice a week during the outpatient phase for weight-management skills training and follow-up with study staff. It is expected that volunteers will lose between 5 and 9% of their starting weights during this time. At the end of the weight loss phase, volunteers will be readmitted to the research hospital for a final 2-week stay. Body weight will be maintained at the new, lower weight, and volunteers will undergo repeat testing on the study diet. At the conclusion of testing, volunteers will be discharged from the hospital and the study will conclude.
TESTING:
During this study, a number of tests and procedures will be performed at various times. These will include:
- Questionnaires about physical activity, eating habits, attitudes about food, quality-of-life, and hunger
- A 3-day record of food intake at baseline
- Use of a pedometer (step-counter) to assess usual physical activity
- Blood tests (including blood sugar, insulin levels, cholesterol levels, fat hormones, and inflammatory markers)
- 24-hour ambulatory blood pressure monitoring
- Measurement of energy expenditure (the rate at which a body burns calories)
- Noninvasive assessment of body composition before and after weight loss
- Insulin clamp procedures (during which insulin and sugar are infused through a vein to help determine how sensitive a person's body is to insulin)
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10021
- Rockefeller University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Nonsmoking men and premenopausal women, ages 18-45
- Body mass index ≥ 27 kg/m2
- Body weight < 200 kg
- Evidence of insulin resistance, as suggested by any one of the following:
- Fasting glucose ≥ 100 mg/dL
- Impaired glucose tolerance, with a glucose concentration of ≥ 140 mg/dL 2 hours after a 75-gram oral glucose challenge
- A fasting insulin concentration ≥ 9 mIU/L
- At least two of the following:
- Waist circumference > 35" in women or > 40" in men
- Prehypertension or hypertension, with BP > 120/80 mmHg but < 145/90 mmHg on 2 antihypertensive agents or less
- TG > 150 but < 500 mg/dL
- HDL < 40 mg/dL in men or < 50 mg/dL in women
- Willingness to consume only study food and drink for the duration of the study and to be randomized to one of the three diets
- Willingness to maintain consistent intake of coffee and/or tea during the inpatient periods
- Willingness to avoid the use of all over-the-counter or prescription vitamins, dietary supplements, and herbal products during the study, with the exception of the multivitamin supplement (Flintstones® Plus Iron.)
- Willingness to continue current antihypertensive medications at the same dose and schedule throughout the study, unless a change is advised.
- Willingness to avoid the use of non-steroidal anti-inflammatory drugs including low-dose daily aspirin, for at least ten days prior to the first admission and during each admission.
- Willingness to avoid the use of acetaminophen (Tylenol) and furosemide (Lasix) for at least 48 hours prior to and during the 24-hour urine collection.
- Willingness to avoid the use of sulfonamide antibiotics for at least 1 week prior to and during the 24-hour urine collection.
Exclusion Criteria:
- Current tobacco smoking
- History of a bleeding disorder
- Findings suggestive of cardiovascular disease.
- Blood pressure ≥ 145/90 mmHg after 10 minutes of rest on two or more screening visits, or treatment with three or more antihypertensive agents at any blood pressure.
- Fasting glucose ≥ 165 mg/dL, glycosylated hemoglobin > 8%, or any treatment with oral hypoglycemic agents, insulin sensitizing agents , insulin, incretin mimetics, amylin analogues, or endocannabinoid receptor antagonists.
- History of chronic glucocorticoid use, oral glucocorticoid use for more than 5 days in the previous year, or anticipated treatment with oral or intravenous glucocorticoids during the study period.
- Current treatment with weight loss medications.
- History of bariatric surgery
- Current treatment with any cholesterol-lowering medications.
- Hyperthyroidism or untreated hypothyroidism.
- Pregnancy, desired pregnancy, or lactation within the study period.
- Peri- or postmenopausal status.
- Obstructive sleep apnea.
- Active gallstone disease
- Known history of chronic hepatitis, or liver enzymes more than 2.5 times the upper limit of normal
- Known infection with HIV or confirmed positive test for HIV antibody
- Inflammatory bowel disease, active cancer, or any other medical condition that may cause significant acute weight loss or gain
- Sustained weight loss > 5% of body weight in the previous two months, or sustained weight loss > 10% of body weight in the previous six months
- History of kidney stones
- Renal disease, as evidenced by a serum creatinine above the normal limit on more than one screening visit
- Serum calcium, potassium, or magnesium above the normal limit, confirmed on two screening tests
- Seizure disorder
- History of any inpatient psychiatric admission within the past two years
- History of schizophrenia, psychosis, or bipolar disorder
- History of anorexia nervosa or bulimia nervosa or a history of medical or psychological treatment for an eating disorder
- Severe binge eating disorder
- Active moderate to severe depression.
- History of alcohol or drug abuse within the previous two years
- History, physical, or laboratory findings suggestive of any other medical or psychological condition that would, in the opinion of the principal investigator, make the candidate ineligible for the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Average American Diet
|
The reduced-calorie diets will provide at least the Recommended Daily Allowance (RDA) for protein (0.8 g/kg/day).
|
|
Active Comparator: The DASH diet
|
The DASH diet was originally conceived as the optimal diet for individuals with hypertension, based on epidemiologic and clinical trial data suggesting a beneficial effect of plant-based diets on blood pressure It is a diet rich in fruits, vegetables, whole grains, and low-fat dairy products, with moderate amounts of nuts, legumes, fish, and poultry.
Consumption of red meat, sweets, and sugary beverages is limited.
As a result, the DASH diet contains more potassium, magnesium, calcium, and fiber and less total fat, saturated fat, cholesterol, simple sugars, and sodium than the average American diet
|
|
Active Comparator: The Low Glycemic Index Diet
The carbohydrate content of a low GI diet can vary, but many advocates of low GL popular diets suggest a macronutrient profile that is 40% carbohydrate, 30% protein, and 30% fat.
These low GL diets are lower in carbohydrate content and higher in protein content than the average American diet.
Low GL diets typically contain ample amounts of fruits and vegetables, moderate quantities of nuts, legumes, lean meats, fish, and reduced-fat dairy products, and scant amounts of refined grains, potatoes, and sweets
|
The carbohydrate content of a low GI diet can vary, but many advocates of low GL popular diets suggest a macronutrient profile that is 40% carbohydrate, 30% protein, and 30% fat.
These low GL diets are lower in carbohydrate content and higher in protein content than the average American diet.
Low GL diets typically contain ample amounts of fruits and vegetables, moderate quantities of nuts, legumes, lean meats, fish, and reduced-fat dairy products, and scant amounts of refined grains, potatoes, and sweets
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in insulin sensitivity over time
Time Frame: Baseline, Inpatient Days 1-19, Inpatient final 2 weeks
|
Baseline, Inpatient Days 1-19, Inpatient final 2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in body weight
Time Frame: Baseline, Outpatient 2 weeks, inpatient 1-19 days, outpatient 8 weeks and inpatient 2 weeks
|
Baseline, Outpatient 2 weeks, inpatient 1-19 days, outpatient 8 weeks and inpatient 2 weeks
|
|
Change in blood sugar levels
Time Frame: baseline and final inpatient 2 weeks
|
baseline and final inpatient 2 weeks
|
|
Change in blood pressure
Time Frame: Baseline, Inpatient days 1-19 and inpatient 2 weeks
|
Baseline, Inpatient days 1-19 and inpatient 2 weeks
|
|
Change in cholesterol levels
Time Frame: Baseline and outpatient 8 weeks
|
Baseline and outpatient 8 weeks
|
|
Change in inflammatory markers
Time Frame: Baseline, Inpatient days 1-19 and outpatient 2 weeks
|
Baseline, Inpatient days 1-19 and outpatient 2 weeks
|
|
Diet satisfaction
Time Frame: day 88
|
day 88
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lisa Neff, MD, Rockefeller University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LNE 595-0107
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)United States
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
Abant Izzet Baysal UniversityNot yet recruitingPRIMARY HYPERTENSIONTurkey (Türkiye)
-
SingHealth PolyclinicsNanyang PolytechnicEnrolling by invitationHypertension,EssentialSingapore
-
Hacettepe UniversityBozok UniversityCompletedHypertension | Arterial Hypertension | Systemic HypertensionTurkey (Türkiye)
-
BackBeat Medical IncNot yet recruitingHypertension, Systolic | Hypertension (HTN) | Heart Failure With Preserved Ejection Fraction (HFpEFGeorgia
-
Xuanwu Hospital, BeijingNot yet recruiting
-
Shenzhen Salubris Pharmaceuticals Co., Ltd.Not yet recruiting
-
Instituto de Cardiologia do Rio Grande do SulCompletedHypertension (HTN) | Hypertension ArterialBrazil
Clinical Trials on Reduced calorie American Diet
-
Vanderbilt UniversityCompletedChronic Kidney DiseaseUnited States
-
University of Colorado, DenverSierra NeuropharmaceuticalsCompleted
-
The Cleveland ClinicCompletedObesity | Cardiovascular Disease | Fatty Liver | HypercholesterolemiaUnited States
-
Stanford UniversityCompletedInflammatory Bowel Diseases | Diet Modification | Crohn DiseaseUnited States
-
The First Affiliated Hospital of Xiamen UniversityActive, not recruitingImpaired Glucose Regulation | Overweight/Obese | Time-restricted EatingChina
-
Texas Tech UniversityCompleted
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
University of Alabama at BirminghamCompletedHypertension | Obesity | Diabetes | HyperlipidemiaUnited States
-
Robert C. Atkins FoundationCompletedObesity | Overweight | Type 2 Diabetes MellitusUnited States
-
ShionogiCompleted